Fresenius Kabi Breaks Into Brazilian Biosimilars Market

Strikes State-Private Adalimumab Deal With Fiocruz/Bio-Manguinhos And Bionovis

Brazil health ministry sign
Fresenius’ Idacio will be the company’s first biosimilar on the Brazilian market • Source: Shutterstock

More from Deals

More from Business